Take a look at our previous reports:

Annual Report 2021

Inlicensing to further strengthen the inflammation franchise

In April 2020, we announced a global collaboration with Ryvu focused on the discovery and development of novel small molecule drugs in inflammation. In December 2021, we exercised our exclusive option to license IP developed by Ryvu. Pursuant to this option exercise, Galapagos is granted exclusive worldwide rights to continue the research, development and commercialization of the program based on compounds discovered and developed by Ryvu.

In August 2020, we announced a global collaboration with Scipher Medicine to advance novel drug targets identified by Scipher for the treatment of IBD. We will jointly validate a suite of novel IBD targets discovered by Scipher, after which we have the exclusive option to progress up to five targets into drug discovery and development. Under the terms of the agreement, we will retain the rights for the discovery, development, and commercialization of therapeutics for the selected target(s).

IBD
Inflammatory Bowel Disease. This is a general term for an autoimmune disease affecting the bowel, including CD and UC. CD affects the small and large intestine, while UC affects the large intestine. Both diseases involve inflammation of the intestinal wall, leading to pain, bleeding, and ultimately, in some cases, surgical removal of part of the bowel